The disruption of the Keap1‐Nrf2 interaction stabilizes Nrf2 and promotes Nrf2 nuclear accumulation following treatment with ferroptosis‐inducing compounds, which decreases the sensitivity of cancer cells to ferroptosis induction.51 SLC7A11, a key component of system xc−, is also a target of Nrf2 and is up‐regulated when Nrf2 is activated.52 ARF is a tumour suppressor gene that activates p53 in tumour cells. The gene discussed is KEAP1; the disease is cancer.